AERI:NSD-Aerie Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 17.25

Change

0.00 (0.00)%

Market Cap

USD 0.81B

Volume

0.48M

Average Target Price

USD 28.50 (+65.22%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD10.59B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

N/A

USD4.40B 60.60 454.68
CRON Cronos Group Inc

N/A

USD3.01B 37.00 N/A
TLRY Tilray, Inc

N/A

USD2.95B N/A N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.77B 18.94 43.86
ORGO Organogenesis Holdings Inc

N/A

USD2.74B 133.88 72.55
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.71B 16.08 12.68
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.68B 13.43 7.93

ETFs Containing AERI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.68% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.68% 78% C+ 77% C+
Trailing 12 Months  
Capital Gain 15.00% 53% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.00% 53% F 22% F
Trailing 5 Years  
Capital Gain 12.23% 67% D+ 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.23% 64% D 30% F
Average Annual (5 Year Horizon)  
Capital Gain 3.33% 66% D 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.33% 64% D 38% F
Risk Return Profile  
Volatility (Standard Deviation) 74.65% 26% F 21% F
Risk Adjusted Return 4.46% 60% D- 29% F
Market Capitalization 0.81B 75% C 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 33.77 6% F 4% F
Price / Cash Flow Ratio -12.51 73% C 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -191.81% 16% F 6% F
Return on Invested Capital -54.56% 30% F 16% F
Return on Assets -22.77% 35% F 17% F
Debt to Equity Ratio 877.72% 6% F 1% F
Technical Ratios  
Short Ratio 11.36 12% F 4% F
Short Percent 20.49% 8% F 8% F
Beta 0.72 86% B 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector